ES2173096T3 - Composicion farmaceutica peletizada. - Google Patents

Composicion farmaceutica peletizada.

Info

Publication number
ES2173096T3
ES2173096T3 ES93915549T ES93915549T ES2173096T3 ES 2173096 T3 ES2173096 T3 ES 2173096T3 ES 93915549 T ES93915549 T ES 93915549T ES 93915549 T ES93915549 T ES 93915549T ES 2173096 T3 ES2173096 T3 ES 2173096T3
Authority
ES
Spain
Prior art keywords
weight
approximately
core
active ingredient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915549T
Other languages
English (en)
Inventor
Angelo Mario Morella
Grant Wayne Heinicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
FH Faulding and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd
Application granted granted Critical
Publication of ES2173096T3 publication Critical patent/ES2173096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA EN FORMA DE PASTILLA DE LIBERACION SOSTENIDA QUE CONTIENE UN ELEMENTO NUCLEO QUE INCLUYE APROXIMADAMENTE DE UN 0,1 A UN 95% EN PESO, EN BASE AL PESO TOTAL DEL ELEMENTO NUCLEO, DE UN INGREDIENTE ACTIVO DE BAJA SOLUBILIDAD ACUOSA, APROXIMADAMENTE DE UN 0,1 A UN 55% EN PESO DE UN AGENTE AGLUTINANTE; APROXIMADAMENTE DE UN 5 A UN 99% EN PESO DE UNA SEMILLA NUCLEO; Y UN REVESTIMIENTO NUCLEO, PARA EL ELEMENTO NUCLEO, QUE INCLUYE APROXIMADAMENTE DE UN 30 A UN 97% EN PESO, EN BASE AL PESO TOTAL DE REVESTIMIENTO NUCLEO, EXCLUIDA LA SUSTANCIA DE RELLENO, DE UN POLIMERO ENTERICO; APROXIMADAMENTE DE UN 3 A UN 50% EN PESO DE UN POLIMERO INSOLUBLE; Y DE UN 0 A UN 50% APROXIMADAMENTE EN PESO DE UN PLASTIFICANTE, EN DONDE EL POLIMERO ENTERICO CONTIENE AL MENOS UN 70% EN PESO APROXIMADAMENTE DEL PESO TOTAL DEL POLIMERO ENTERICO Y EL POLIMERO INSOLUBLE; Y EL REVESTIMIENTO NUCLEO ES TAL QUE EL INGREDIENTE ACTIVO SE LIBERA DE FORMA CONTROLADA DURANTE UN PERIODO DE TIEMPO PROLONGADOEN EL INTESTINO PERO NO SE LIBERA SUSTANCIALMENTE EN EL ENTORNO ACIDO DEL ESTOMAGO Y LOS NIVELES EN SANGRE DEL INGREDIENTE ACTIVO SE MANTIENEN DENTRO A NIVEL TERAPEUTICO DURANTE UN MAYOR PERIODO DE TIEMPO.
ES93915549T 1992-08-05 1993-07-23 Composicion farmaceutica peletizada. Expired - Lifetime ES2173096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPL392192 1992-08-05

Publications (1)

Publication Number Publication Date
ES2173096T3 true ES2173096T3 (es) 2002-10-16

Family

ID=3776337

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915549T Expired - Lifetime ES2173096T3 (es) 1992-08-05 1993-07-23 Composicion farmaceutica peletizada.

Country Status (11)

Country Link
US (1) US5800836A (es)
EP (1) EP0653935B1 (es)
JP (1) JPH07509702A (es)
AT (1) ATE217188T1 (es)
CA (1) CA2141582C (es)
DE (1) DE69331906T2 (es)
ES (1) ES2173096T3 (es)
NZ (1) NZ253999A (es)
SG (1) SG42869A1 (es)
WO (1) WO1994003160A1 (es)
ZA (1) ZA935650B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
EP0689840A1 (de) * 1994-06-28 1996-01-03 Spirig Ag Pharmazeutische Präparate Neues orales Erythromycinbase enthaltendes Arzneimittel
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US7687542B2 (en) 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
US6974595B1 (en) 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
DE19715594A1 (de) 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
DE19728249C2 (de) * 1997-07-02 2001-05-03 Georgios Pandalis Produkt aus einem Kern und mindestens einer ein Naturharz enthaltenden Umhüllung, Steckkapsel, Verfahren zur Herstellung einer Filmtablette, Weichkapsel, Steckkapsel und Verwendung von Naturharzen
IL139541A0 (en) * 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000095709A (ja) * 1998-09-25 2000-04-04 Shin Etsu Chem Co Ltd 水系コーティング剤及び固形医薬製剤の製造方法
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
CA2277407A1 (en) * 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
CA2383220C (en) 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
GB0000482D0 (en) * 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
CA2796884A1 (en) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
CA2438641A1 (en) * 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US7101569B2 (en) * 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030165564A1 (en) * 2001-10-29 2003-09-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
DK2204168T3 (en) * 2003-04-07 2015-04-07 Supernus Pharmaceuticals Inc Tetracycline for administration once a day
US7520489B2 (en) 2003-06-17 2009-04-21 Filtertek Inc. Fluid handling device and method of making same
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102004027924A1 (de) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Arzneiform, enthaltend den Wirkstoff Cholylsarcosin
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7939561B2 (en) 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens
US7700125B2 (en) 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
US20100021549A1 (en) * 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
FR2945947B1 (fr) * 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2827843B1 (en) 2012-03-20 2016-05-25 Laboratorios Bagó S.A. Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
CN103393604B (zh) * 2013-07-22 2015-04-01 南通广泰生化制品有限公司 枸橼酸他莫昔芬肠溶颗粒
CN103349648B (zh) * 2013-07-22 2015-03-25 南通广泰生化制品有限公司 枸橼酸他莫昔芬肠溶片
JP7147523B2 (ja) * 2018-12-06 2022-10-05 三生医薬株式会社 造粒方法
EP4037666B1 (en) 2020-12-08 2024-05-01 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
WO2023044024A1 (en) * 2021-09-17 2023-03-23 Novelstar Pharmaceuticals Inc. Novel ph dependent coating drug delivery system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU477515B2 (en) * 1973-01-17 1975-07-17 Sterling Pharmaceuticals Pty. Limited Enteric coating
JPS5518694B2 (es) * 1973-04-02 1980-05-21
DE2327629A1 (de) * 1973-05-30 1974-12-12 Siemens Ag Durchfuehrungsisolator fuer hochspannungseinrichtungen und verfahren zu seiner herstellung
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
JPS5910512A (ja) * 1982-07-09 1984-01-20 Tanabe Seiyaku Co Ltd 徐放性マイクロカプセルおよびその製法
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
WO1986000306A1 (en) * 1982-12-29 1986-01-16 Sansho Seiyaku Co., Ltd. Kojic acid derivatives and whitening cosmetics containing same
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4751226A (en) * 1985-09-12 1988-06-14 Fujisawa Pharmaceutical Co., Ltd. Pyrazoloisoquinoline derivatives, plant growth regulating compositions, and method of use therefor
JPS62135419A (ja) * 1985-12-06 1987-06-18 Ikeda Mohandou:Kk ジクロフエナク塩の粒状組成物及びその製造法
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
SE460946B (sv) * 1987-03-16 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av kinidinglukonat
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
WO1991000688A1 (en) * 1989-07-07 1991-01-24 Vsesojuzny Nauchno-Issledovatelsky Institut Selskokhozyaistvennoi Biotekhnologii Method for sterilization of plant anthers
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
DE19545702C2 (de) * 1995-12-07 1999-05-12 Horsch Maschinen Gmbh Werkzeuganordnung für Bodenbearbeitungsgeräte

Also Published As

Publication number Publication date
EP0653935B1 (en) 2002-05-08
DE69331906T2 (de) 2002-12-19
ZA935650B (en) 1994-03-07
DE69331906D1 (de) 2002-06-13
ATE217188T1 (de) 2002-05-15
SG42869A1 (en) 1997-10-17
JPH07509702A (ja) 1995-10-26
US5800836A (en) 1998-09-01
CA2141582C (en) 2003-09-30
CA2141582A1 (en) 1994-02-17
NZ253999A (en) 1996-07-26
EP0653935A4 (en) 1995-06-07
EP0653935A1 (en) 1995-05-24
WO1994003160A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
ES2173096T3 (es) Composicion farmaceutica peletizada.
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
US4289751A (en) Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2811571B1 (fr) Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
DE69629797D1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
PT809512E (pt) Solucoes farmaceuticas salinas nao inorganicas para administracao endonasal de uma calcitonina
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
EE03740B1 (et) Modifitseeritud vabanemisega oraalne 5-ASA sisaldav farmatseutiline kompositsioon soolehaiguste ravimiseks
GR3021936T3 (en) Pharmaceutical composition comprising a medicament and a water-swellable polymer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 653935

Country of ref document: ES